Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction A Pooled Analysis of 5 Randomized Control Trials by Frazier, Camille G. et al.
H
e
2
a
i
r
F
D
U
S
C
M
2
Journal of the American College of Cardiology Vol. 49, No. 13, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
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Associations of Gender and Etiology With
Outcomes in Heart Failure With Systolic Dysfunction
A Pooled Analysis of 5 Randomized Control Trials
Camille G. Frazier, MD,* Karen P. Alexander, MD,* L. Kristin Newby, MD, MHS,*
Susan Anderson, MS,† Erik Iverson, MS,† Milton Packer, MD,‡ Jay Cohn, MD,§
Sidney Goldstein, MD, Pamela S. Douglas, MD*
Durham, North Carolina; Madison, Wisconsin; Dallas, Texas; Minneapolis, Minnesota; and Detroit, Michigan
Objectives This study sought to explore the gender-related differences in etiology and outcomes in chronic heart failure (HF)
patients from 5 randomized trials.
Background Each year, 550,000 new cases of HF are identified; however, there remain limited data on gender-related differ-
ences in etiology and outcomes among patients with HF with systolic dysfunction.
Methods We analyzed data from 8,791 men and 2,851 women randomized in 5 clinical trials (PRAISE [Prospective Ran-
domized Amlodipine Survival Evaluation], PRAISE-2, MERIT-HF [Metoprolol Extended Release Randomized Inter-
vention Trial in Heart Failure], VEST [Vesnarinone Trial], and PROMISE [Prospective Randomized Milrinone Sur-
vival Evaluation]) to explore gender-related differences in etiology (ischemic vs. nonischemic) and outcomes
(all-cause mortality and death or all-cause hospitalization). Hazard ratios (HR), 95% confidence intervals (CIs),
and Kaplan-Meier survival curves were generated by gender and etiology.
Results A total of 18% of ischemic and 31% of nonischemic patients were women. Irrespective of etiology, women were
older, more ethnically diverse, and had higher systolic blood pressures, more diabetes, and severe HF symp-
toms, but less often smoked or had prior myocardial infarctions than men. Mean ejection fractions were similar
between women (23.6%) and men (23.2%). The 1-year Kaplan-Meier survival estimates varied by gender and
etiology (female nonischemics, HR 0.88 [95% CI 0.85 to 0.89]; female ischemics, HR 0.83 [95% CI 0.81 to
0.85]; male nonischemics, HR 0.84 [95% CI 0.83 to 0.85]; male ischemics, HR 0.79 [95% CI 0.78 to 0.81]).
After adjustment, female gender (HR 0.77 [95% CI 0.69 to 0.85]) and nonischemic etiology (HR 0.80 [95% CI
0.72 to 0.89]) were associated with longer survival time. Time to death or hospitalization was longer among
nonischemics (HR 0.83 [95% CI 0.78 to 0.89], p  0.0001); however, female gender was not significantly asso-
ciated with the composite outcome (HR 1.01 [95% CI 0.95 to 1.08]).
Conclusions Our data clarify that outcomes differ by both gender and etiology among patients with HF with systolic dysfunc-
tion. Understanding these differences may lead to better management of HF patients and improved overall
prognosis. (J Am Coll Cardiol 2007;49:1450–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.041l
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feart failure (HF) affects 5 million people in the U.S., with
stimated direct and indirect costs reaching $29.6 billion in
006 (1). Each year, 550,000 new cases of congestive HF
re diagnosed. Advances in medical management have
mproved the prognosis of HF patients; however, survival
emains poor (2–12). Although 5-year mortality with HF is
rom the *Division of Cardiovascular Medicine, Duke University Medical Center,
urham, North Carolina; †Department of Biostatistics and Medical Informatics,
niversity of Wisconsin-Madison, Madison, Wisconsin; ‡University of Texas,
outhwestern Medical Center, Dallas, Texas; §University of Minnesota Medical
enter, Minneapolis, Minnesota; and Henry Ford Health System, Detroit,
ichigan. Lynn Warner-Stevenson, MD, acted as Guest Editor for this article.f
Manuscript received June 15, 2006; revised manuscript received November 17,
006, accepted November 17, 2006.ower among women than men (45% vs. 59%), women now
ccount for the majority (62.5%) of deaths from HF in the
.S. because of shifting demographics (1,2).
Subset analyses of large-scale trials have attempted to
rovide insight into gender-related differences in clinical
rofiles and predictors of outcome, but individually, these
nalyses are limited by small numbers of female participants
nd differences in systolic function and definitions of etiol-
gy (13–16). A pooled analysis of multiple trials provides an
pportunity to further explore gender-related differences in
tiology, clinical profiles, and outcomes among patients
ith HF with depressed left ventricular (LV) ejection
raction (LVEF). Therefore, we combined the databases
rom 5 randomized clinical trials in chronic HF with LV
s
d
H
t
M
T
p
2
h
o
b
a
w
M
T
P
a
t
e
d
c
w
c
n
t
s
s
m
i
z
d
m
l
d
c
E
a
p
s
P
1
(
1
d
A
p
A
m
p
E
s
S
w
a
v
m
a
c
m
t
c
v
w
c
t
a
r
g
s
b
a
i
L
c
p
a
o
o
m
T
w
p
r
s
i
c
h
g
c
a
s
m
m
t
C
s
R
S
T
L
I
(
b
3
A
C
1451JACC Vol. 49, No. 13, 2007 Frazier et al.
April 3, 2007:1450–8 Gender Differences in HF With Systolic Dysfunctionystolic dysfunction (Metoprolol Extended Release Ran-
omized Intervention Trial in Heart Failure [MERIT-
F], Prospective Randomized Amlodipine Survival Evalua-
ion Study [PRAISE], PRAISE-2, Prospective Randomized
ilrinone Survival Evaluation [PROMISE], and Vesnarinone
rial [VEST]) in order to: 1) explore differences in clinical
rofiles by gender and etiology (ischemic vs. nonischemic);
) investigate characteristics associated with mortality and
ospitalization; and 3) examine differences in these clinical
utcomes by gender and etiology. In so doing, we sought to
etter understand the independent associations of gender
nd HF etiology with clinical outcomes among patients
ith LV systolic dysfunction.
ethods
rials. We pooled data from the MERIT-HF, PRAISE,
RAISE-2, PROMISE, and VEST trials, which represent
convenience sample of chronic HF trials coordinated
hrough the authors and their institutions. Protocol design,
ntry criteria, and baseline characteristics for each trial are
isplayed in Table 1 (17–20). Etiology of HF was used as
lassified on each trial’s case report form. Ischemic etiology
as defined as the presence of coronary artery disease
onfirmed by coronary arteriography or radionuclide scan-
ing, or suspected based on a history of myocardial infarc-
ion (MI). Nonischemic etiology was defined as HF with
ystolic dysfunction in the absence of history of MI or
ignificant coronary artery disease on angiography. Enroll-
ent medications collected from the case report forms
ncluded aspirin, beta-blockers, angiotensin-converting en-
yme inhibitors, calcium channel blockers, nitrates, digoxin,
iuretics, warfarin, anti-arrhythmics, and hormone replace-
ent therapy. Studies varied slightly in the variables col-
ected and their definitions. Shared variables with similar
efinitions were chosen to be combined across trials to
reate a common data set for pooling patient-level data.
ach common variable had 5% missing information in
ny one trial. For the Cox proportional hazards models
resented here, only variables that were collected in all
tudies were included as covariates.
ooled patient-level data. From the pooled population of
1,719 patients, those missing information on HF etiology
n  77) were excluded, leaving a final study population of
1,642 patients (8,791 men and 2,851 women). The median
uration of follow-up was 352 (range 222 to 901) days.
ll-cause mortality and all-cause hospitalization. The
rimary outcome of interest was time to all-cause mortality.
secondary outcome was time to first event of all-cause
ortality or all-cause hospitalization as a composite end
oint. We also assessed time to all-cause hospitalization.
nd points were accepted as collected by the individual
tudies without reclassification or further validation.
tatistical analysis. Baseline characteristics and outcomes
ere compared across subgroups by gender (female vs. male)nd HF etiology (ischemic vs. nonischemic). Continuous dariables are presented using
eans with standard deviations
nd categorical variables as per-
entages. Comparisons were
ade using Wilcoxon rank-sum
ests for continuous variables and
hi-square tests for categorical
ariables.
Kaplan-Meier survival curves
ere created for mortality, the
omposite of mortality or hospi-
alization, and hospitalization
lone. Stratified multivariable Cox proportional hazards
egression models were used to test the association among
ender, HF etiology, and outcomes. The Cox models were
tratified by study and treatment to allow for differing
aseline hazard rates between studies. Results are displayed
s hazard ratios (HR) (95% confidence intervals). Variables
ncluded in the modeling process were age, race/ethnicity,
VEF, New York Heart Association (NYHA) functional
lass, ischemic (vs. nonischemic) etiology, systolic blood
ressure, heart rate, and weight. Gender-by-etiology inter-
ction terms were evaluated in separate models including all
f the aforementioned covariates. The Cox models devel-
ped on the overall population were compared with similar
odels, stratified by study, and fit to placebo patients only.
hese models resulted in effects for the terms in common,
hich were similar in direction and magnitude in the
lacebo-only and all-randomized groups. The robustness of
esults was also assessed by systematically dropping each
tudy from the pooled data. The hazard ratios for all
ncluded covariates in the resulting models were reassuringly
onsistent for mortality, the composite end point of death or
ospitalization, and hospitalization alone. In addition, the
ender-by-etiology interaction terms were examined in
ovariate-adjusted models fit to each study. For all analyses
nd the modeling, a p value of 0.05 was considered
tatistically significant. No adjustments were made for
ultiple comparisons. The summary statistics and Cox
odels were done using SAS/STAT software, version 9 of
he SAS System for Linux (SAS Institute, Cary, North
arolina). Graphics were created using version 2.1 of the R
oftware (R Development Core Team, Vienna, Austria).
esults
tudy Population
he pooled study population included 24% women, mean
VEF was 23%, and 85% had NYHA functional class III or
V symptoms at enrollment. Median follow-up was 352
range 222 to 901) days. Baseline characteristics are shown
y gender and HF etiology in Table 2. Among women,
9.8% had ischemic and 60.2% had nonischemic etiology.
mong men, 57.1% were ischemic and 42.9% nonischemic.
ompared with men, women were older; more ethnically
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
NYHA  New York Heart
Associationiverse; and had higher systolic blood pressure, more dia-
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Gender Differences in HF With Systolic Dysfunction April 3, 2007:1450–8etes, and more advanced HF symptoms. Women less often
ad a history of smoking or prior MI. The mean LVEF was
imilar among women and men (23.6% vs. 23.2%, respectively).
Compared with an ischemic etiology, nonischemic HF
atients were younger, more often black and female, and
ad higher body mass index and lower systolic blood
ressure. They had less diabetes and tobacco use. The group
ean QRS duration was prolonged, 120 ms in all sub-
roups, but duration varied by etiology and gender.
Medication use at enrollment differed by etiology (Table 2).
iuretic use was high regardless of gender or etiology (range
2% to 96%). Patients with nonischemic etiology reported
ore use of angiotensin-converting-enzyme inhibitors and
igoxin, whereas nitrates, aspirin, and calcium channel
lockers were used less often. Beta-blocker use was low
verall, and use of anti-arrhythmics was more frequent
mong men regardless of etiology. Hormone replacement
herapy was used by 17% of women with ischemic and 21%
f women with nonischemic HF.
linical Outcomes
rimary outcome. Death occurred in 2,400 patients during
ollow-up. Kaplan-Meier 1-year survival estimates varied by
ender and etiology (female nonischemics HR 0.88 [95%
onfidence interval (CI) 0.85 to 0.89], female ischemics HR
.83 [95% CI 0.81 to 0.85], male nonischemics HR 0.84
95% CI 0.83 to 0.85], male ischemics HR 0.79 [95% CI
.78 to 0.81]. The unadjusted survival curves for men and
omen diverged early, and the difference persisted among
onischemic patients, but the difference was less prominent
mong ischemic patients. Compared with men, women had
etter survival, whether ischemic or nonischemic etiology.
aplan-Meier probabilities for mortality by gender and
tiology are shown in Figure 1.
econdary outcomes. Crude survival curves for the com-
osite of mortality or hospitalization differed by etiology,
ut not by gender. Ischemic patients did worse than
onischemic patients. Figure 2 shows the Kaplan-Meier
robabilities for the composite of mortality or hospitaliza-
ion by gender. Nonischemic patients had shorter time to
ospitalizations than ischemic patients. Gender differences
ere not apparent among nonischemic patients; however,
mong ischemic patients, time to hospitalization was
horter among women (Fig. 3).
ultivariable Associations With Clinical Outcomes
rimary outcome. Baseline characteristics associated with
urvival time are shown in Table 3. Characteristics associ-
ted with worse survival included advancing age, higher
eart rate, and NYHA functional class IV symptoms.
emale gender, nonischemic etiology, non-Caucasian eth-
icity, higher systolic blood pressure, and higher LVEF
ere associated with better survival.
In assessing associations with time to mortality among
schemic and nonischemic groups independently, among
ischemic patients, higher heart rates, NYHA functionalDe T
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April 3, 2007:1450–8 Gender Differences in HF With Systolic Dysfunctionlass IV symptoms, and greater age were associated with
horter time to death. Higher systolic blood pressure and
VEF, non-Caucasian ethnicity, female gender, and greater
eight were associated with better survival among ischemic
atients. Among nonischemic patients, increasing age,
YHA functional class IV symptoms, and higher heart rate
ere associated with shorter survival time, while female
ender and increased systolic blood pressure and LVEF
ere associated with improved survival. The individual
redictors were similar for men and women, except that
Demographics and Clinical Profiles by Gender
Table 2 Demographics and Clinical Profiles
Ischemi
(n  5,02
57%
Age variables
Age (mean/SD) 65.4 (9.2
Age, yrs (groups %)
65 43%
65–74 41%
75 16%
Race/ethnicity (%)
Caucasian 93
Black 5
Asian 1
Other 1
Baseline measurements
Weight, kg (mean/SD) 81.9 (15
Body mass index, kg/m2 (mean/SD) 26.8 (4.4
Cardiothoracic ratio (mean/SD) 0.55 (0.0
QRS width (mean/SD) 132 (49
NYHA functional class of heart failure (%)
II 17
III 70
IV 13
Medical history (%)
Prior myocardial infarction 83
Diabetes mellitus 32
Prior tobacco 84
Clinical presentation (mean/SD)
Systolic blood pressure 121 (19
Diastolic blood pressure 73 (11
Heart rate 80 (12
Ejection fraction (%) 23.9 (7.2
Medications (%)
Angiotensin-converting enzyme inhibitor 89
Beta-blocker 3
Diuretic 92
Digoxin 80
Nitrates 59
Calcium channel blockers 12
Aspirin 51
Warfarin 40
Antiarrhythmics 15
Hormone replacement therapy 1
Abbreviations as in Table 1.on-Caucasian ethnicity was not significant for women. bA gender-by-etiology interaction term was significant in
he Cox model for time to death (p 0.048). Descriptively,
ime to death was longer for women than men among
atients with both ischemic and nonischemic etiologies, but
he difference between men and women was greater in the
onischemic group.
econdary outcomes. TIME TO DEATH OR HOSPITALIZA-
ION. Baseline characteristics associated with time to death
r hospitalization are shown in Table 4. Characteristics
ssociated with shorter time to death or hospitalization for
nder
ale Female
Nonischemic
(n  3,770)
43%
Ischemic
(n  1,134)
40%
Nonischemic
(n  1,717)
60%
58.3 (12.5) 66.7 (9.6) 60.3 (12.5)
65% 38% 60%
25% 40% 28%
9% 22% 12%
75 86 73
20 11 23
1 1 1
4 2 4
87.4 (20.2) 64.7 (15.2) 72.9 (19.3)
28.0 (5.9) 26.2 (5.3) 27.7 (6.7)
0.56 (0.08) 0.59 (0.08) 0.60 (0.09)
126.8 (44.8) 126.7 (60.9) 130.8 (40.4)
13 15 9
73 69 74
14 16 17
9 77 8
32 42 35
77 55 52
119 (19.0) 126 (21.2) 121 (19.3)
75 (11.5) 74 (11.7) 73 (11.2)
84 (14.6) 82 (11.6) 85 (13.6)
22.3 (7.1) 24.7 (7.3) 22.9 (6.8)
94 86 94
4 3 4
95 94 96
90 79 91
33 62 33
8 12 9
24 48 24
44 37 38
13 9 10
1 17 21by Ge
M
c
1)
)
.7)
)
7)
.7)
.7)
.0)
.1)
)oth ischemic and nonischemic patients included increasing
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Gender Differences in HF With Systolic Dysfunction April 3, 2007:1450–8ge, NYHA functional class IV symptoms, and higher heart
ate. Higher systolic blood pressure and LVEF were asso-
iated with greater time to hospitalization or death. Female
ender was not significantly associated with the composite
nd point among ischemic patients (HR 1.05, 95% CI 0.95
o 1.16) or among nonischemic patients (HR 0.97, 95% CI
.90 to 1.06). In assessing gender-related differences in
actors associated with death or hospitalization, NYHA
unctional class IV symptoms and increased heart rate were
ssociated with increased morbidity and mortality among
oth genders, but age was only significantly associated
mong men (HR 1.13, 95% CI 1.09 to 1.16). Nonischemic
tiology, higher systolic blood pressure, and higher ejection
raction were associated with longer time to events for both
enders. A gender-by-etiology interaction term was not
ignificant in the Cox model for time to death or hospital-
zation (p  0.06); however, a trend was evident. Descrip-
ively, for this interaction, time to hospitalization or death
as shorter for women than men among patients with
schemic etiology but was longer in women than men in
onischemics. For men and women, nonischemics had
onger time to the composite, but for women, time to event
as longer than among men.
IME TO HOSPITALIZATION. Characteristics associated
ith shorter time to hospitalization included NYHA func-
ional class IV symptoms and higher heart rates. Female
ender was not significantly associated with time to hospi-
Figure 1 Kaplan-Meier Probabilities of Survival by Etiology of H
F  female; Isc  ischemic; M  male; NIsc  nonischemic.alization (HR 1.04, 95% CI 0.97 to 1.11), but when axamined by etiology, female gender was a significant
redictor of hospitalization for ischemic patients (HR 1.15,
5% CI 1.04 to 1.27). Older age was associated with shorter
ime to hospitalization among men but not among women.
onischemic etiology and higher systolic blood pressure
nd LVEF were associated with greater time to hospital-
zation overall and among both women and men.
iscussion
he 2,851 women enrolled in these trials of advanced
hronic HF with systolic dysfunction were older, more likely
o have nonischemic HF, and more ethnically diverse
ompared with men. Women also had more severe HF
ymptoms, higher systolic blood pressure, and more diabe-
es. In addition, whereas female gender was associated with
etter survival across HF etiologies, gender was not associ-
ted with time to hospitalization or the composite outcome
f death or hospitalization. For the end point of mortality,
dvanced age, ischemic etiology, and advanced NYHA
ymptoms were equally strong predictors of death among
omen and men. However, advanced NYHA symptoms
nd ischemic etiology were among the variables most
trongly associated with composite end point of death or
ospitalization among women, whereas older age, ischemic
tiology, and advanced symptoms had the strongest associ-
tions with earlier death or hospitalization among men.
onischemic etiology was associated with lower mortality
Failure and Gendereartnd greater time to hospitalization in both genders. Thus,
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April 3, 2007:1450–8 Gender Differences in HF With Systolic Dysfunctionifferences exist in symptom severity and clinical character-
stics, as well as event-free survival, by patient gender and
F etiology among chronic HF patients with systolic
ysfunction included in these analyses. This may have
mportant implications for understanding prognosis and
uiding management in patients with HF with LV systolic
ysfunction.
The women in this analysis were more likely to have a
onischemic etiology compared with men (60.2% vs. 42.8%,
espectively). This predominance of nonischemic etiology
mong women is similar to previous reports (14–16,21).
omen in our analysis had higher blood pressure and more
iabetes, suggesting that chronic hypertension and diabetes
ay be important contributing mechanisms to the develop-
ent of systolic HF among women. Adaptation to pressure
verload and remodeling from cardiac hypertrophy to dila-
ion and its progression to systolic dysfunction as a result of
ypertension in addition to microvascular disease and dif-
erences in hypertrophic response associated with diabetes
ay differ among women and men (22–27).
Although the trials in our pooled database recruited for
evere HF, the higher prevalence of NYHA functional class
II and IV symptoms among women also may relate to
ifferences in HF etiology or differences in hemodynamics
n women compared with men. Hemodynamic studies have
hown higher end-diastolic pressures despite lower volumes
n women, suggesting greater alterations in the pressure-
Figure 2 Kaplan-Meier Probabilities of the Composite of Death
Abbreviations as in Figure 1.olume relation in women (28–31). In addition, perception hf disease, description of symptoms, and adaptation differ
mong women and men and may influence these character-
stics and contribute to symptom severity and hospitaliza-
ions among women, particularly with ischemic disease
32–37). Lastly, reports have indicated that pharmacologic
herapy differs between women and men (38,39). In our
nalysis, women more frequently received diuretic therapy and
ess frequently received angiotensin-converting enzyme inhib-
tors before enrollment, which may contribute to persistent
ymptoms. These mechanisms may either explain the variance
n etiology of HF observed between the genders in this
ymptomatic population or suggest opportunities for clinical
are across the spectrum of HF with systolic dysfunction.
Unlike previous analyses in HF indicating that women
ad higher LVEF than men, which was used to explain
heir relatively better survival (13–16,21,32), our data dem-
nstrated better survival among women compared with men
n a population with similar LVEF. This persisted even after
djusting for covariates. The greatest gender-related survival
ifference was observed between nonischemic women and
en; however, a difference was also evident among ischemic
atients. Although additional risk factors not addressed may
ontribute to these differences, our data provide new insight
nto gender-related differences in HF by etiology among
atients with marked systolic dysfunction that should be
xplored further.
Whether gender is associated with hospitalization in HF
spitalization by Etiology of Heart Failure and Genderor Hoas been controversial. Many studies suggest that women
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ospitalization compared with men (13–16,21,32). How-
ver, other analyses suggest there are no differences by
ender (40,41). In our analysis, we found that female gender
as not significantly associated with hospitalizations or the
omposite death or hospitalization outcome. Heart failure
tiology appeared to better discriminate these outcomes.
fter adjustment for comorbidities, our study demonstrated
hat female gender was not a significant predictor of time to
ospitalization alone or the combined end point of death or
ospitalization among patients with severe LV systolic
ysfunction. Only after accounting for etiology was female
ender significantly associated with earlier hospitalizations.
he differing results in other studies may relate to the
Figure 3 Kaplan-Meier Probabilities of Hospitalization by Etiolo
Abbreviations as in Figure 1.
Multivariable Predictors of Death: Hazard Ratios
Table 3 Multivariable Predictors of Death: H
Ove
Age (per 10-yr increase) 1.
Ethnicity (non-Caucasian) 0.
Female 0.
Nonischemic etiology 0.
NYHA functional class IV 1.
Heart rate (per 10-beats/min increase) 1.
Weight (per 10-kg increase) 0.
Systolic blood pressure (per 10-mm Hg increase) 0.
Left ventricular ejection fraction (per 10% increase) 0.NYHA  New York Heart Association.roportion of patients with ischemic etiology or preserved
ystolic function.
We also found that women had a longer time to death
ompared with men, but the protective effect of gender was
reater among nonischemic patients. The existence of such
n interaction between HF etiology and gender has only
arely been evaluated previously. Adams et al. (42) evaluated
ender and etiology of HF in 557 HF patients. This
ong-term observational study noted a significant associa-
ion between gender and survival, but through further
nalysis, HF etiology was the strongest predictor of survival,
ith a significant gender-by-etiology interaction. These
uthors concluded that the variance in survival was mostly
ue to etiology of HF rather than gender.
Heart Failure and Gender
h 95% Confidence Intervals
Ratios With 95% Confidence Intervals
 11,487) Male (n  8,682) Female (n  2,805)
15–1.25) 1.19 (1.13–1.25) 1.22 (1.12–1.33)
77–0.97) 0.86 (0.76–0.99) 0.85 (0.67–1.06)
69–0.85) — —
72–0.89) 0.81 (0.72–0.91) 0.76 (0.61–0.94)
63–1.99) 1.78 (1.60–2.00) 1.87 (1.54–2.29)
02–1.08) 1.05 (1.01–1.08) 1.07 (1.00–1.14)
94–0.99) 0.97 (0.94–1.00) 0.95 (0.89–1.00)
83–0.88) 0.86 (0.83–0.88) 0.84 (0.80–0.89)
67–0.76) 0.72 (0.67–0.78) 0.69 (0.60–0.80)gy ofWit
azard
rall (n
20 (1.
86 (0.
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80 (0.
80 (1.
05 (1.
96 (0.
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April 3, 2007:1450–8 Gender Differences in HF With Systolic Dysfunctiontudy limitations. Potential limitations in this observa-
ional study include heterogeneity of the included studies,
election bias, treatment effect, and time period and dura-
ion and follow-up of included trials. The MERIT-HF
tudy included more NYHA functional class II patients
41%) than the other four studies, and the PRAISE II trial
tudied exclusively nonischemic cardiomyopathy patients
nd had a higher mean LVEF than the other studies.
herefore, the pooled analysis methodology could introduce
eterogeneity in the large group evaluation. However, this
as addressed by merging the data at the patient level to
llow use of and adjustment for enrolling demographics,
atient profiles, medication use, and outcomes from the
riginal randomized controlled trials. In addition, we em-
loyed analyses stratified by trial. Also, all the pooled studies
nrolled patients with chronic HF with depressed EF.
ecause a substantial portion of women with HF have
reserved systolic function, this could lead to under-
epresentation of women in the included studies. Despite
his concern, our pooled analyses included 24% women.
Another potential limitation in this analysis was includ-
ng all patients enrolled in the studies. Differential response
o experimental treatments by gender could bias our results.
o address this, we developed Cox proportional hazards
odels stratified by study drug treatment and also analyzed
he data, pooling only the placebo groups, and found similar
esults as for our overall analyses (data not shown). Median
ollow-up in the pooled trials was 352 days. This short
uration of follow-up could limit the number of recorded
vents, potentially affecting our ability to detect differences
f they exist. However, with a total of 2,400 deaths, we do
ot believe power to detect differences was a substantial
imitation. Lastly, the time period of the trials we pooled
panned more than a decade. This was addressed by
erging data at the patient level, stratifying the analyses by
rial, and testing concomitant therapies in our adjustment
odels.
onclusions
his analysis of pooled data from five large, randomized,
ontrolled trials in HF with LV systolic dysfunction adds
ultivariable Predictors of Death or Hospitalization: Hazard Ratios
Table 4 Multivariable Predictors of Death or Hospitalization: Ha
Overall
Age (per 10-yr increase) 1.10 (1.08–1.13) 1
Ethnicity (non-Caucasian) 1.06 (0.99–1.13) 1
Female 1.01 (0.95–1.08)
Nonischemic 0.83 (0.79–0.89) 0
NYHA functional class IV 1.54 (1.44–1.65) 1
Heart rate (per 10-beats/min increase) 1.06 (1.04–1.08) 1
Weight (per 10-kg increase) 1.00 (0.98–1.01) 0
Systolic blood pressure (per 10-mm Hg increase) 0.94 (0.92–0.95) 0
Left ventricular ejection fraction (per 10% increase) 0.82 (0.78–0.85) 0
YHA  New York Heart Association.larity to existing research on gender-related differences intiology and outcomes in this population. Previously, better
urvival among women had been attributed to better systolic
unction, and women were thought to have more hospital-
zation over time. Our study demonstrates that, even with
ystolic dysfunction, women have better survival compared
ith men and that hospitalization over time is influenced more
y etiology than gender. These observations should lead to
learer understanding of the management and outcomes of
atients with HF and systolic dysfunction.
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